Diversity Supplement to Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
药物提示反应性β-肾上腺素能调节的多样性补充:神经和行为机制
基本信息
- 批准号:10838177
- 负责人:
- 金额:$ 5.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdjuvant AnalgesicAdrenergic AgentsAdrenergic AntagonistsAdrenergic beta-AntagonistsAdultAttentionBehavioral MechanismsBrain regionCessation of lifeCigaretteCigarette SmokerClinicalCuesDevelopmentDrug ModulationDrug usageExposure toFutureImageInterventionLaboratoriesMediatingModelingMotivationNicotine WithdrawalPerfusionPharmaceutical PreparationsPlacebosPre-Clinical ModelProceduresPropranololProtocols documentationResearchRestSamplingScanningSmokerSmokingSmoking BehaviorSmoking Cessation InterventionStimulusUnited StatesWorkaddictionbehavioral responsebeta-adrenergic receptorcerebrovascularcravingcue reactivitydesignfunctional MRI scanimprovedneuralneuromechanismnicotine patchparent grantpharmacologicpre-clinicalresponsesmoking cessationsmoking cue
项目摘要
PROJECT SUMMARY/ABSTRACT (FROM PARENT GRANT)
More than 50% of smokers attempt to quit smoking each year, but even with intensive treatment the
overwhelming majority will return to smoking within six months. Given over 480,000 deaths each year in the
United States alone are directly attributable to smoking, there is a tremendous need for improved smoking
cessation interventions. β-adrenergic receptor antagonists have received substantial attention as a potential
treatment for addiction across both pre-clinical and clinical models. Traditional smoking cessation medications
are very effective for alleviating nicotine withdrawal but much less effective at addressing the influence of
environmental cues on smoking behavior. One key advantage of β-adrenergic drugs is that they target a
different mechanism than established treatments, acting to directly curb the influence of these environmental
cues on smoking motivation. This creates the potential for adjuvant medication interventions, whereby β-
adrenergic drugs are used in combination with medications targeting nicotine withdrawal to maximize potential
efficacy. A recently completed study in our laboratory supports this idea, demonstrating that acute
administration of propranolol reduces cue-provoked craving, suppresses neural response to smoking stimuli
(e.g. cigarettes, lighters), and alters connectivity between key brain regions shown to mediate effects in pre-
clinical models. This application seeks to expand upon this work by examining the impact of β-adrenergic
drugs on neural and behavioral response to smoking cues in a larger sample using a design that enables
examination of the effects of a β-adrenergic antagonist alone and in combination with an established smoking
cessation medication targeting nicotine withdrawal. Adult cigarette smokers (N = 80) will systematically
photograph their personal smoking contexts using procedures we have developed and validated. They will
then undergo four functional magnetic resonance imaging (fMRI) scans during which they will be exposed to
smoking stimuli, including images of their personal smoking contexts. Prior to each scan, they will receive
either: 1) Nicotine Patch + β-Adrenergic Antagonist; 2) Placebo Patch + β-Adrenergic Antagonist; 3) Nicotine
Patch + Placebo Drug; and 4) Placebo Patch + Placebo Drug. Analyses will examine the effects of these
medications on craving and neural activation in response to smoking cues (Aim 1), as well as neural
connectivity (Aim 2). In addition, an exploratory aim will examine whether observed effects are mediated by
changes in cerebrovascular perfusion or neural connectivity at rest (Exploratory Aim 3). Results from this
translational project will provide valuable information on the neural underpinnings of β-adrenergic medications.
It will directly inform the development of a new line of pharmacological agents for smoking cessation and
provide a deeper understanding of mechanisms that can be used to help refine future intervention protocols.
项目总结/摘要(来自PAYNET GRANT)
每年有超过50%的吸烟者试图戒烟,但即使经过强化治疗,
绝大多数人会在六个月内重新吸烟。考虑到世界上每年有超过48万人死亡,
仅美国就直接归因于吸烟,因此非常需要改进吸烟
停止干预。β-肾上腺素能受体拮抗剂作为一种潜在的治疗药物已经受到了广泛的关注。
在临床前和临床模型中的成瘾治疗。传统戒烟药物
对于缓解尼古丁戒断非常有效,但对于解决
环境因素对吸烟行为的影响β-肾上腺素能药物的一个关键优势是它们靶向于
不同的机制比既定的治疗,直接遏制这些环境的影响,
吸烟动机的线索。这为辅助药物干预创造了可能性,
肾上腺素能药物与靶向尼古丁戒断的药物联合使用,
功效我们实验室最近完成的一项研究支持了这一观点,表明急性
给予普萘洛尔可减少提示诱发的烟瘾,抑制对吸烟刺激的神经反应
(e.g.香烟,打火机),并改变了关键大脑区域之间的连接,这些区域被证明可以介导预
临床模型本申请旨在通过检查β-肾上腺素能受体对细胞的影响来扩展这项工作。
在更大的样本中使用一种设计,
检查β-肾上腺素能拮抗剂单独使用和与已确定的吸烟者联合使用的效果
针对尼古丁戒断的戒烟药物。成年吸烟者(N = 80)将系统地
使用我们开发和验证的程序拍摄他们的个人吸烟环境。他们将
然后接受四次功能性磁共振成像(fMRI)扫描,在此期间,他们将暴露于
吸烟刺激,包括他们个人吸烟环境的图像。在每次扫描之前,他们将收到
任一:1)尼古丁贴剂+ β-肾上腺素能拮抗剂; 2)安慰剂贴剂+ β-肾上腺素能拮抗剂; 3)尼古丁
贴剂+安慰剂药物;和4)安慰剂贴剂+安慰剂药物。分析将检查这些影响
药物对渴望和神经激活响应吸烟线索(目标1),以及神经
连通性(目标2)。此外,探索性目的将检查观察到的效应是否由以下因素介导:
静息时脑血管灌注或神经连接的变化(探索性目标3)。结果从这个
翻译项目将提供关于β-肾上腺素能药物的神经基础的有价值的信息。
它将直接为开发一种新的戒烟药物提供信息,
更深入地了解可用于帮助完善未来干预方案的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Anthony Oliver其他文献
Jason Anthony Oliver的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Anthony Oliver', 18)}}的其他基金
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
药物提示反应性的β-肾上腺素调节:神经和行为机制
- 批准号:
10446411 - 财政年份:2022
- 资助金额:
$ 5.71万 - 项目类别:
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
药物提示反应性的β-肾上腺素调节:神经和行为机制
- 批准号:
10618895 - 财政年份:2022
- 资助金额:
$ 5.71万 - 项目类别:
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology toReal-World Behavior
尼古丁戒断和奖励处理:将神经生物学与现实世界行为联系起来
- 批准号:
10439154 - 财政年份:2017
- 资助金额:
$ 5.71万 - 项目类别:
Neurobehavioral substrates of propranolol's effects on drug cue reactivity
普萘洛尔对药物提示反应性影响的神经行为底物
- 批准号:
9387245 - 财政年份:2017
- 资助金额:
$ 5.71万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 5.71万 - 项目类别:
Research Grant